Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy?

Kazuyuki Yuge, Eiji Kikuchi, Kazuhiro Matsumoto, Toshikazu Takeda, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: The effect of local immunotherapy with bacille Calmette-Guérin in elderly patients with non-muscle-invasive bladder cancer has not yet been fully evaluated. The aim of the present study was to evaluate whether patients' age influences the response to bacille Calmette-Guérin treatment for the prevention of tumor recurrence and whether the side effects were tolerable. Methods: We reviewed 1252 cases with non-muscle-invasive bladder cancer treated with transurethral bladder tumor resection, and 447 cases who underwent bacille Calmette- Guérin immunotherapy were included. The associations between patient age or pathological findings and tumor recurrence were determined. Side effects were classified as minor or major and were analyzed on the basis of their incidences in each age group. Results: The patients were divided into four age categories: younger than 55 (n = 86), 55-64 (n = 143), 65-74 (n = 132) and equal or older than 75 years (n = 86). The Kaplan-Meier curves of recurrence-free survival rates demonstrated that patients aged 55-64 had been continuously tumor-free than the equal or older than 75 group. The presence of previous bladder cancer and Grade 3 were independent predictors for tumor recurrence; however, patients' age was not selected. The incidence of fever was slightly higher and that of cystitis was lower in the younger group. Conclusions: Age does not certainly affect recurrence in patients with bladder cancer treated with bacille Calmette-Guérin therapy. The related side effects in the elderly patients were almost equal to those in the younger. With careful monitoring, bacille Calmette-Guérin therapy is safe even in elderly patients.

Original languageEnglish
Article numberhyq241
Pages (from-to)565-570
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume41
Issue number4
DOIs
Publication statusPublished - 2011 Apr

Fingerprint

Mycobacterium bovis
Urinary Bladder Neoplasms
Immunotherapy
Recurrence
Neoplasms
Cystitis
Incidence
Fever
Therapeutics
Survival Rate
Age Groups

Keywords

  • Age
  • Bacille Calmette-Guérin
  • Intravesical immunotherapy
  • Non-muscle-invasive bladder cancer
  • Side effect

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy? / Yuge, Kazuyuki; Kikuchi, Eiji; Matsumoto, Kazuhiro; Takeda, Toshikazu; Miyajima, Akira; Oya, Mototsugu.

In: Japanese Journal of Clinical Oncology, Vol. 41, No. 4, hyq241, 04.2011, p. 565-570.

Research output: Contribution to journalArticle

@article{2bb8a2004aba463f849295b4570be635,
title = "Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy?",
abstract = "Objective: The effect of local immunotherapy with bacille Calmette-Gu{\'e}rin in elderly patients with non-muscle-invasive bladder cancer has not yet been fully evaluated. The aim of the present study was to evaluate whether patients' age influences the response to bacille Calmette-Gu{\'e}rin treatment for the prevention of tumor recurrence and whether the side effects were tolerable. Methods: We reviewed 1252 cases with non-muscle-invasive bladder cancer treated with transurethral bladder tumor resection, and 447 cases who underwent bacille Calmette- Gu{\'e}rin immunotherapy were included. The associations between patient age or pathological findings and tumor recurrence were determined. Side effects were classified as minor or major and were analyzed on the basis of their incidences in each age group. Results: The patients were divided into four age categories: younger than 55 (n = 86), 55-64 (n = 143), 65-74 (n = 132) and equal or older than 75 years (n = 86). The Kaplan-Meier curves of recurrence-free survival rates demonstrated that patients aged 55-64 had been continuously tumor-free than the equal or older than 75 group. The presence of previous bladder cancer and Grade 3 were independent predictors for tumor recurrence; however, patients' age was not selected. The incidence of fever was slightly higher and that of cystitis was lower in the younger group. Conclusions: Age does not certainly affect recurrence in patients with bladder cancer treated with bacille Calmette-Gu{\'e}rin therapy. The related side effects in the elderly patients were almost equal to those in the younger. With careful monitoring, bacille Calmette-Gu{\'e}rin therapy is safe even in elderly patients.",
keywords = "Age, Bacille Calmette-Gu{\'e}rin, Intravesical immunotherapy, Non-muscle-invasive bladder cancer, Side effect",
author = "Kazuyuki Yuge and Eiji Kikuchi and Kazuhiro Matsumoto and Toshikazu Takeda and Akira Miyajima and Mototsugu Oya",
year = "2011",
month = "4",
doi = "10.1093/jjco/hyq241",
language = "English",
volume = "41",
pages = "565--570",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy?

AU - Yuge, Kazuyuki

AU - Kikuchi, Eiji

AU - Matsumoto, Kazuhiro

AU - Takeda, Toshikazu

AU - Miyajima, Akira

AU - Oya, Mototsugu

PY - 2011/4

Y1 - 2011/4

N2 - Objective: The effect of local immunotherapy with bacille Calmette-Guérin in elderly patients with non-muscle-invasive bladder cancer has not yet been fully evaluated. The aim of the present study was to evaluate whether patients' age influences the response to bacille Calmette-Guérin treatment for the prevention of tumor recurrence and whether the side effects were tolerable. Methods: We reviewed 1252 cases with non-muscle-invasive bladder cancer treated with transurethral bladder tumor resection, and 447 cases who underwent bacille Calmette- Guérin immunotherapy were included. The associations between patient age or pathological findings and tumor recurrence were determined. Side effects were classified as minor or major and were analyzed on the basis of their incidences in each age group. Results: The patients were divided into four age categories: younger than 55 (n = 86), 55-64 (n = 143), 65-74 (n = 132) and equal or older than 75 years (n = 86). The Kaplan-Meier curves of recurrence-free survival rates demonstrated that patients aged 55-64 had been continuously tumor-free than the equal or older than 75 group. The presence of previous bladder cancer and Grade 3 were independent predictors for tumor recurrence; however, patients' age was not selected. The incidence of fever was slightly higher and that of cystitis was lower in the younger group. Conclusions: Age does not certainly affect recurrence in patients with bladder cancer treated with bacille Calmette-Guérin therapy. The related side effects in the elderly patients were almost equal to those in the younger. With careful monitoring, bacille Calmette-Guérin therapy is safe even in elderly patients.

AB - Objective: The effect of local immunotherapy with bacille Calmette-Guérin in elderly patients with non-muscle-invasive bladder cancer has not yet been fully evaluated. The aim of the present study was to evaluate whether patients' age influences the response to bacille Calmette-Guérin treatment for the prevention of tumor recurrence and whether the side effects were tolerable. Methods: We reviewed 1252 cases with non-muscle-invasive bladder cancer treated with transurethral bladder tumor resection, and 447 cases who underwent bacille Calmette- Guérin immunotherapy were included. The associations between patient age or pathological findings and tumor recurrence were determined. Side effects were classified as minor or major and were analyzed on the basis of their incidences in each age group. Results: The patients were divided into four age categories: younger than 55 (n = 86), 55-64 (n = 143), 65-74 (n = 132) and equal or older than 75 years (n = 86). The Kaplan-Meier curves of recurrence-free survival rates demonstrated that patients aged 55-64 had been continuously tumor-free than the equal or older than 75 group. The presence of previous bladder cancer and Grade 3 were independent predictors for tumor recurrence; however, patients' age was not selected. The incidence of fever was slightly higher and that of cystitis was lower in the younger group. Conclusions: Age does not certainly affect recurrence in patients with bladder cancer treated with bacille Calmette-Guérin therapy. The related side effects in the elderly patients were almost equal to those in the younger. With careful monitoring, bacille Calmette-Guérin therapy is safe even in elderly patients.

KW - Age

KW - Bacille Calmette-Guérin

KW - Intravesical immunotherapy

KW - Non-muscle-invasive bladder cancer

KW - Side effect

UR - http://www.scopus.com/inward/record.url?scp=79953730598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953730598&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyq241

DO - 10.1093/jjco/hyq241

M3 - Article

C2 - 21233106

AN - SCOPUS:79953730598

VL - 41

SP - 565

EP - 570

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 4

M1 - hyq241

ER -